307 related articles for article (PubMed ID: 31286527)
41. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings.
Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK
J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293
[TBL] [Abstract][Full Text] [Related]
42. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
43. [Lopinavir/ritonavir in new initial antiretroviral treatment strategies].
Rolón MJ; Figueroa MI; Sued O; Cahn P
Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():7-11. PubMed ID: 25542869
[TBL] [Abstract][Full Text] [Related]
44. Renal safety of coformulated tenofovir/emtricitabine vs other nucleoside analogues in combination therapy in antiretroviral-naive patients aged 50 years or older in Spain: The TRIP study.
Pedrol E; Caro-Murillo AM; Castaño MA; Riera M; Olalla J; Domingo P; Arazo P; Gómez-Sirvent JL; Pulido F; Romero-Palacios A; Aguirrebengoa K; Vera F; Ferrer P; Blanco Ramos JR
HIV Clin Trials; 2015; 16(1):43-8. PubMed ID: 25777189
[TBL] [Abstract][Full Text] [Related]
45. Transmitted drug resistance to NRTIs and risk of virological failure in naïve patients treated with integrase inhibitors.
Borghetti A; Ciccullo A; Lombardi F; Baldin G; Belmonti S; Prosperi M; Incardona F; Heger E; Borghi V; Sönnerborg A; Zazzi M; De Luca A; Di Giambenedetto S
HIV Med; 2021 Jan; 22(1):22-27. PubMed ID: 32964671
[TBL] [Abstract][Full Text] [Related]
46. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India.
Karade S; Sen S; Sashindran VK
AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915
[TBL] [Abstract][Full Text] [Related]
47. Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage.
Benson C; Emond B; Lefebvre P; Lafeuille MH; Côté-Sergent A; Tandon N; Chow W; Dunn K
J Manag Care Spec Pharm; 2020 Feb; 26(2):129-141. PubMed ID: 31747358
[TBL] [Abstract][Full Text] [Related]
48. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
49. Reduction of CD8 T Cell Functionality but Not Inhibitory Capacity by Integrase Inhibitors.
Richter E; Bornemann L; Korencak M; Alter G; Schuster M; Esser S; Boesecke C; Rockstroh J; Gunzer M; Streeck H
J Virol; 2022 Mar; 96(5):e0173021. PubMed ID: 35019724
[TBL] [Abstract][Full Text] [Related]
50. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database.
Ruzicka DJ; Kuroishi N; Oshima N; Sakuma R; Naito T
BMC Infect Dis; 2019 Jun; 19(1):505. PubMed ID: 31182050
[TBL] [Abstract][Full Text] [Related]
51. Pretreatment HIV-drug resistance in Mexico and its impact on the effectiveness of first-line antiretroviral therapy: a nationally representative 2015 WHO survey.
Ávila-Ríos S; García-Morales C; Matías-Florentino M; Romero-Mora KA; Tapia-Trejo D; Quiroz-Morales VS; Reyes-Gopar H; Ji H; Sandstrom P; Casillas-Rodríguez J; Sierra-Madero J; León-Juárez EA; Valenzuela-Lara M; Magis-Rodríguez C; Uribe-Zuñiga P; Reyes-Terán G;
Lancet HIV; 2016 Dec; 3(12):e579-e591. PubMed ID: 27658867
[TBL] [Abstract][Full Text] [Related]
52. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
53. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
54. Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy.
Davy-Mendez T; Eron JJ; Zakharova O; Wohl DA; Napravnik S
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):111-115. PubMed ID: 28628528
[TBL] [Abstract][Full Text] [Related]
55. Short Communication: Dolutegravir-Based Regimens Are Active in Integrase Strand Transfer Inhibitor-Naive Patients with Nucleoside Reverse Transcriptase Inhibitor Resistance.
Demarest J; Underwood M; St Clair M; Dorey D; Brown D; Zolopa A
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):343-346. PubMed ID: 29444582
[TBL] [Abstract][Full Text] [Related]
56. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011-2017.
Korten V; Gökengin D; Eren G; Yıldırmak T; Gencer S; Eraksoy H; Inan D; Kaptan F; Dokuzoğuz B; Karaoğlan I; Willke A; Gönen M; Ergönül Ö;
AIDS Res Ther; 2021 Jan; 18(1):4. PubMed ID: 33422112
[TBL] [Abstract][Full Text] [Related]
57. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
Hill A; Sawyer W
HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
[TBL] [Abstract][Full Text] [Related]
58. Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients.
Gianotti N; Poli A; Nozza S; Galli L; Galizzi N; Ripa M; Merli M; Carbone A; Spagnuolo V; Lazzarin A; Castagna A
BMC Infect Dis; 2017 Nov; 17(1):723. PubMed ID: 29145807
[TBL] [Abstract][Full Text] [Related]
59. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.
Jacobson K; Ogbuagu O
Medicine (Baltimore); 2018 Oct; 97(43):e13016. PubMed ID: 30412140
[TBL] [Abstract][Full Text] [Related]
60. Real-world effectiveness of WHO recommended first-line antiretroviral therapies: a cohort study from a middle-income country.
Meireles G; Nobre AA; Cardoso SW; Velasque L; Veloso VG; Grinsztejn B; Luz PM
AIDS Care; 2023 Dec; 35(12):1891-1903. PubMed ID: 37001113
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
